Bracco S.p.A.
Bracco S.p.A.
09/21/2022 | Press release | Distributed by Public on 09/21/2022 11:00
Wednesday, September 21, 2022 Bracco Announces FDA Approval of Gadopiclenol Injection, a New Macrocyclic High Relaxivity Gadolinium Based Contrast Agent which will be[...]
Bracco Announces FDA Approval of Gadopiclenol Injection, a New Macrocyclic High Relaxivity Gadolinium Based Contrast Agent which will be commercialized as VUEWAY ™
Monroe Township, NJ , 09/21/2022
VUEWAY injection is highly stable and shows the highest relaxivity among gadolinium based contrast agents available for clinical use i